ArticleFrontiers in cardiovascular medicine2025

Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal.

F H van Bruggen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.